Ayesha Anwaar
Nephrology · Tulsa, OKNPI 1487007449
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.8% of the total across 129 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 21 manufacturers, the largest accounting for just 18.0% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,242, 2.1 times the $591 reported in 2023.
Across 129 payments — averaging $22.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$517
- Amgen$401
- Travere Therapeutics, Inc.$225
- Boehringer Ingelheim$173
- Otsuka America Pharmaceutical, Inc.$167
- Vifor Pharma, Inc.$155
- plus $1K from 15 others
What the payments were for
- Food & beverage$2,77297%
- Education$923%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 22 | $517 |
| Amgen | 18 | $401 |
| Travere Therapeutics, Inc. | 10 | $225 |
| Boehringer Ingelheim | 8 | $173 |
| Otsuka America Pharmaceutical, Inc. | 8 | $167 |
| Vifor Pharma, Inc. | 7 | $155 |
| Calliditas Therapeutics US Inc. | 7 | $153 |
| Veloxis Pharmaceuticals, Inc. | 5 | $152 |
| Pharmacosmos Therapeutics Inc. | 6 | $142 |
| Novartis | 6 | $142 |
| Novo Nordisk | 6 | $122 |
| OPKO Pharmaceuticals, LLC | 6 | $99 |
| Bayer | 4 | $84 |
| GSK | 3 | $60 |
| Vantive US Healthcare LLC | 1 | $48 |
| Ardelyx, Inc. | 3 | $46 |
| Aurinia Pharma U.S., Inc. | 2 | $45 |
| ANI Pharmaceuticals, Inc. | 2 | $43 |
| Daiichi Sankyo Inc. | 2 | $34 |
| Cormedix Inc. | 2 | $33 |
| Fresenius USA Marketing, Inc. | 1 | $20 |
How this compares
$2,863 in reported general payments places this provider in the 55th percentile of 106 nephrology providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 41 | $29,397 |
| JardianceEmpagliflozin | 15 | $11,817 |
| VeltassaPatiromer Calcium Sorbitex | 12 | $7,803 |
| Sevelamer Carbonate | 17 | $4,653 |
| Cinacalcet Hcl | 11 | $3,954 |
| Bumetanide | 84 | $2,486 |
| ProsolParenteral Amino Acid 20% No.1 | 18 | $2,354 |
| Chlorthalidone | 83 | $1,254 |
| Fluoxetine Hcl | 11 | $618 |
| Losartan Potassium | 89 | $599 |
| Tamsulosin Hcl | 48 | $487 |
| Amlodipine Besylate | 79 | $455 |
| Furosemide | 76 | $409 |
| Lisinopril | 36 | $296 |
| Trazodone Hcl | 12 | $289 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga | $517 | $29,39741 claims |
| Boehringer IngelheimJardiance | $173 | $11,81715 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 106 nephrology providers in Oklahoma.
Other nephrology in Tulsa
- Sunil AgrawalTulsa$40K
- Pranay KathuriaTulsa$21K
- Kevin FuTulsa$14K
- Diptesh GuptaTulsa$13K
- Janet RussellTulsa$12K
- Bobby MuthalalyTulsa$12K
- Narottam RegmiTulsa$12K
- Alpana PasrichaTulsa$9K
- Reza AzadiTulsa$9K
- Christine WilsonTulsa$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.